November 16, 2018
NapaJen Pharma, a biotherapeutics company leveraging its proprietary immune cell-targeted oligonucleotide delivery technology, announced on November 15 the dosing of the first patient in a PI clinical trial of the oligonucleotide therapeutic NJA-730 being conducted in Australia. NJA-730 combines a...read more